|
|
List of sponsors 
If you are interested in sponsorship opportunities at this event then please contact:
Ince Saleem, Sponsorship manager
Email: ince.saleem@terrapinn.com
Tel: +44 (0) 20 7539 4323
Fax: +44 (0) 7984 479 740
|
Gold sponsor
|
Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification, especially in the biopharmaceutical industry for the production of biotech and biopharmaceutical products.
Pall's Life Sciences Group is fully integrated to offer product lines that start in the laboratory with drug discovery, gene manipulation and proteomics applications, and extend into drug development, process scale up, through to full drug manufacturing production and patient delivery. Pall's extensive expertise helps its customers throughout the drug approval regulatory process, and its filtration systems and validation services offer drug manufacturers the quickest and surest path through the regulatory process and onto the market. As Mr Jerold M. Martin, Senior Vice President and Global Technical Director for Pall Life Sciences' BioPharmaceuticals division said, "Pall Corporation is committed to developing the most advanced, cost-effective virus filtration products that maximize customers' opportunity for success."
|
DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6® human cell line as a production platform for recombinant proteins and monoclonal antibodies. The combination of the PER.C6® human cell line and DSM’s manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market.
|
Silver sponsor
|
Invitrogen provides essential life science technologies and services for disease research, drug discovery, and commercial bio-production. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bio-informatics and cell biology-placing Invitrogen's products in nearly every major laboratory in the world. Through its Bioproduction business Invitrogen focuses on all aspects of the production of biotherapeutics, from early stage process development with it's PD Direct process offering, to testing and bioprocess validation undertaken by BioReliance through to the widest product offering of catalogue and specifically tailored cell culture formulations for up stream cell culture. For more information about Invitrogen, visit the company's web site at www.invitrogen.com.
|
NPIL Pharma is one of the few global custom manufacturing organisations offering fully integrated services, ranging from pre-formulation to commercial manufacture of finished dosage forms, complemented by niche pharma technologies including High Potency Substances. Our Grangemouth site (Scotland, UK) routinely manufactures a wide range of oncology products and through our collaboration with key innovators in this field – and specifically antibody conjugation – is a world leader in the development of viable processes and manufacturing solutions for this important area of medicine.
Our FDA & MHRA approved facilities include five segregated suites for the manufacture of cytotoxic & cytostatic small molecules, and antibody drug conjugates, operating under OEB 4/5 containment levels. Supporting these are experienced R&D, process development and analytical teams, and an established local collaboration for finished drug product, providing you with a fully integrated service for all your HPS needs.
NPIL Pharma – your strategic partner for High Potency & Conjugation outsourcing
|
Supporting partner
|
Cambridge Antibody Technology (CAT) is a biopharmaceutical company using its capabilities and technologies in the discovery and development of new and innovative antibody medicines in selected therapeutic areas to bring improvements to seriously ill patients? lives. CAT employs around 300 people and is based near Cambridge, UK and in Palo Alto, USA.
CAT is a leader in the discovery and development of human therapeutic antibodies and has an?advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. CAT has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company?s strategy to develop a portfolio of antibody-based drugs.
|
|
|
|
